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Abstract
Arbovirus of the Flaviviridae family represents an issue worldwide, particularly 
because it can lead to serious illness and death in some countries. There is still a 
great complexity in obtaining effective therapies and specific and sensitive diag-
nostic tests, due to the high antigenic similarity between them. This similarity may 
account for antibodies cross reactivity which has positive and negative consequences 
for the course of infectious diseases. Among dengue virus (DENV) serotype infec-
tions, the cross-reactivity can increase virus replication and the risk of a severe 
disease by a mechanism known as an antibody-dependent enhancement (ADE). 
The search for serological biomarkers through monoclonal antibodies (MAbs) that 
identify unique viral regions can assist in the differential detection, whereas the 
development of recombinant antibodies with a neutralizing potential can lead to the 
establishment of efficacious treatments. The Phage Display methodology emerged 
as one of the main alternatives for the selection of human MAbs with high affinity 
for a specific target. Therefore, this technology can be a faster alternative for the 
development of specific diagnostic platforms and efficient and safe treatments for 
flavivirus infections. In this context, we propose for this chapter a discussion about 
Phage Display as a strategy to obtain MAbs for DENV and other flaviviruses.
Keywords: antibody, Phage Display, dengue virus, flavivirus, therapy, diagnosis
1. Introduction
When thinking about the development of virus detection and neutralization  
technologies whose bases of action are immunoglobulins, it is necessary to understand 
the structure of the viral particle of interest. In addition to the sequence of amino acid 
residues that make up the target epitopes, their position in the particle and their func-
tion in the process of infection and viral replication influence the design experiments 
aiming the obtantion of antibodies with a diagnostic and therapeutic potential.
The structures of flavivirus have been determined and studied, mainly, by 
combining cryo-electron microscopy with data from X-ray diffraction experiments 
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using crystallography of viral proteins in the presence or not of antibody molecules. 
Results of this combination showed that the flavivirus is composed of a dense icosa-
hedral electron nucleus and a lipid bilayer surrounding it. The genome comprises a 
sequence of ~10,700 nucleotides of a positive-sense RNA that encodes a polyprotein 
that is cleaved in 3 structural proteins, capsid protein (C), membrane protein (M), 
and envelope protein (E), and in 7 nonstructural proteins, NS1, NS2A, NS2B, NS3, 
NS4A, NS4B, and NS5 [1]. The NS1 protein plays a role in viral replication and is 
often shown to be a soluble antigen secreted into the bloodstream, interacting with 
components of the immune system. NS5 is the largest and most conserved non-
structural protein and acts in the transcription process of viral RNA [2, 3].
The icosahedral capsid is small and poorly organized, but it provides enough 
space for the genome and is surrounded by the envelope, so there are few connections 
between these structures, unlike what is found in other viruses. The viral envelope 
consists of two internal and concentric layers of phospholipids and an outer protein 
shell formed by regions of protein M and ectodomains of glycoprotein E organized 
in dimers which present protein determinants for the binding of the virus to the host 
cell (hemagglutination). Protein E contains three domains: domain I (DI), which is 
related to cell tropism and envelope organization; domain II (DII), which comprises 
the dimerization region and the fusion peptide; and domain III (DIII) with the func-
tion of binding to cell receptors, in the initial stage of viral infection [4, 5].
The fusion loop is a highly conserved region between dengue virus (DENV) 
serotypes and all flaviviruses, responsible for the late stage of infection, in which 
the virus interacts with the endosomal membrane, resulting in the release of the 
nucleocapsid in the cytoplasm. When the particle is in the lysosomal vesicle during 
the infection process, a structural reorganization of the viral envelope occurs; the 
fusion loop is exposed and inserted in the lysosomal membrane. After the forma-
tion of the fusion loop contact, protein E starts to organize itself into trimmers, 
resulting in the expansion of the viral particle and the approximation of the viral 
and lysosomal membranes, forming the fusion lipid pore that allows the release of 
the viral genome to the cytoplasm [3, 6, 7].
DENV serotypes show great heterogeneity in the structure of viral proteins. 
However, there is also antigenic similarity between DENV serotypes and, for some 
peptide sequences, between flaviviruses. Phylogeny studies of virus sequences, by 
estimating the antigenic distance between them, concluded that serotypes 1 and 
3 are the most similar, serotype 2 was the second to diverge evolutionarily, and 
serotype 4 is the one that presents greater genetic difference. There is a 32% differ-
ence in the structure of protein E of the four DENV serotypes. Specific mutations in 
the genome result in the antigenic variability found in each serotype [7–9].
Much of the genetic difference between flaviviruses is due to protein E, which 
can show up to 60% difference in its amino acid sequence. In the phylogenetic 
analysis of the viruses, the DENV serotypes are closer to the Zika virus (ZIKV), 
with approximately 45% difference, and have 50 and 60% dissimilarity with West 
Nile virus (WNV) and yellow fever virus (YFV), respectively. DENV and other fla-
viviruses vary dramatically in terms of the amino acid sequence of the glycosylation 
region and the content of glycans added to the surface of E and precursor mem-
brane protein (prM). Many epitopes of protein E are unique to a DENV serotype 
[4, 9–11]. It can also be observed in ZIKV, which has the glycosylation site, in the DI 
of protein E, different in conformation and length of the loop that contains this gly-
cosylation site. The carbohydrate associated with this residue can act as a virus bind-
ing site in host cells. Thus, differences in this region of glycosylation can influence 
cell tropism, infection, and pathogenesis of these viruses [12]. Another important 
characteristic of ZIKV is the insertion of an alanine residue in the carboxyl termina-
tion of DIII, which is associated with an increased stability of this virus [13].
Please use Adobe Acrobat Reader to read this book chapter for free.
Just open this same document with Adobe Reader.
If you do not have it, you can download it here.
You can freely access the chapter at the Web Viewer here.
S curing Connection...Acrobat i  locking documen loading.com
r
File cannot be found.
3Phage Display as a Strategy to Obtain Anti-flavivirus Monoclonal Antibodies
DOI: http://dx.doi.org/10.5772/intechopen.93076
The hydrophobic sequence of the fusion loop appears to be the only epitope 
that is conserved among all flaviviruses; however, the degree of exposure in this 
region varies substantially among viruses [6]. Nonstructural proteins, NS1 and 
NS5, also present some epitopes conserved among the DENV serotypes and other 
members of the flavivirus genus, but their position also varies between viral strains. 
The relationships of antigenic similarity between flaviviruses generate immune 
responses that are configured as cross-reactions with protective or pathological 
characteristics [5, 14, 15].
2. Immunoglobulins
Immunoglobulins, or antibodies, are glycoproteins, expressed on the surface of 
B cells or secreted, that act in the neutralization and elimination of pathogens [16]. 
Antibodies are relatively flexible “Y”-shaped molecules made up of two heavy 
chains and two light chains, joined by an extensive network of non-covalent 
interactions, stabilized by disulfide bonds. Both types of chains are composed of 
constant and variable domains. The constant regions determine the functional 
properties of the antibody, and the variable regions determine the antigen-binding 
site. The light chain consists of a variable portion (VL) and a constant portion (CL) 
that can have two types of domains, kappa (ƙ) or lambda (λ). The heavy chain 
consists of a variable portion (VH) and three or four constant portions, depending 
on the class of the antibody, which are CH1, CH2, CH3, and CH4. The type of heavy 
chain determines the class, or isotype, of antibody, such as IgA, IgG, IgD, IgE, 
and IgM [17].
The antibody molecule can be subdivided into portions of the crystallizable 
fragment (Fc) and antigen-binding fragment (Fab) region. The Fc portion has the 
constant domains (CH2, CH3, CH4), and the Fab portion consists of the VH-CH1 
and VL-CL domains. The Fab portion retains the ability to bind to the antigen, and 
the Fc portion acts to mediate the effector functions of antibodies [17].
Three segments containing variability can be identified in both the VH and VL 
domains. These segments are the hypervariable regions that determine antigen 
specificity and are more commonly called complementarity-determining regions 
(CDRs)—CDR1, CDR2, and CDR3. The combination of CDRs from a VH with 
CDRs from a VL forms the region of interaction with the epitope, called the para-
tope [17]. The variability of the antigen-binding regions is responsible for the ability 
of different antibodies to bind to many structurally diverse antigens [18]. Figure 1 
represents the structure of an IgG immunoglobulin and its domains.
In cognate antigen recognition, some naïve B cells can initiate somatic hypermu-
tation, generating new variable domains, that can be selected based on their ability 
of antigen binding, usually with high affinity compared to germinal domains. After 
antigen recognition, naïve B cells differentiate into antibody-secreting plasma cells. 
These plasma cells secrete antibodies with high affinity and, can differentiate into 
memory B cells. Memory B cells are highly specialized cells for quickly recognizing 
the antigen in subsequent exposure, can persist for years, and provide long-term 
humoral protection for decades. These functional features of memory B cells are the 
basis of effective vaccines [19].
The knowledge about the mechanisms of antibody production and clonal selec-
tion of B cells led to the development of innovative hybridoma technology in 1975 
[20]. The technique is based on the fusion of B lymphocytes with myeloma cells 
giving rise to hybrid cells that produce monoclonal antibodies (MAbs) continuously 
in vitro [21]. Therefore, MAbs are monovalent antibodies, which bind to the same 
epitope and are produced from a single B lymphocyte clone.
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MAbs interact with a single epitope allowing a specific reactivity and affinity 
for target antigens. This feature is a great advantage over polyclonal antibodies, 
which have different epitope specificities and affinities [22, 23]. For this reason, 
MAbs have a broad clinical applicability in therapy for various illness, including 
cancer, transplant rejection, and autoimmune, infectious, hematologic, and cardio-
vascular diseases. Moreover, MAbs can play a significant role in the diagnosis and as 
antibody-drug conjugate for drug delivery. Thus, MAbs are considered a powerful 
tool for a wide range of medical applications.
2.1 Cross-reactivity of antibodies
Antibodies that bind to different flaviviruses are able to promote both the 
neutralization of the infection and the increase of the virus capture, such as by 
the interaction of immune complexes with Fc receptors expressed in certain cell 
types. The creation of alternative routes of entry of the viral particle into cells by 
low-neutralizing antibodies, during secondary infections of flavivirus, results in 
increased levels of viral replication and pathogenicity. This mechanism constitutes a 
phenomenon called antibody-dependent enhancement (ADE) [24, 25].
Different studies have been conducted to understand the effects of cross-
reactive memory antibodies on subsequent flavivirus exposures. Many of them 
reported that the opsonization of the virus with weakly neutralizing antibodies led 
to the increase of the viral production and of pro-inflammatory mediators. This 
could lead to the suppression of the antiviral immune response, worsening the 
clinical condition of the disease [5, 7]. ADE has already been reported in in vitro 
experiments of infection of cells that express Fc receptors and in vivo experiments 
Figure 1. 
Classical structure of an antibody. Structure of a class G immunoglobulin, representing the two portions of 
the molecule: two Fabs that correspond to the antigen-binding fragment and an Fc that corresponds to the 
crystallizable fragment. A type G antibody consists of two heavy polypeptide chains, each containing a VH and 
three constant domains (CH1, CH2, and CH3), and two light chains, each containing a VL and a CL. CDRs are 
three regions of hypervariability present in each of the variable domains. In addition to the natural format of 
the antibody, it is possible to generate recombinant antibodies such as the single-chain variable fragment (scFvs).
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of vaccination with flavivirus [11, 26]. From the results of these experiments, ADE 
is pointed out as one of the main causes of severe forms of DENV infection and of 
the low protection induced by vaccines targeting DENV serotypes [27].
An opposite effect of cross-reacting antibodies has also been demonstrated, 
an increase in protection against secondary infections by flavivirus, which has 
resulted in potent neutralization and rapid induction of affinity maturing immune 
responses against heterologous flaviviruses. Studies in endemic areas of flavivirus 
showed protection against Zika virus infection in patients with a previous experi-
ence with DENV. A humoral response capable of potentially neutralizing both 
species of flavivirus was assembled from the expansion of cross-reaction memory 
B cell clones, even in the absence of DENV circulation. Thus, previous flavivirus 
infections can lead to both cross-neutralization and increased pathogenicity of the 
virus through the formation of interspecific antibody memory [28, 29].
The potential of cross-reaction immunity to trigger protection or pathology 
depends on the profile, quality, and magnitude of the immune responses induced by 
antibodies. The ADE reaction is a factor that should be considered in the develop-
ment of therapeutic antibodies and vaccines for infections by flavivirus. Different 
approaches have been tested to shift the ADE profile to a cross-protection profile in 
heterogeneous infections of these viruses.
3. Phage Display
The principle of the Phage Display is the presentation of libraries of molecules 
on the surface of a bacteriophage (phage), allowing the identification of a wide 
range of biomolecules, including peptides, antibodies, and other proteins. The 
Phage Display methodology was first described in 1985, by George Smith and 
colleagues. Through the expression (display) of polypeptides on the phage surface 
(phage) M13, it was possible to perform the mapping of antibody epitopes by 
screening them using random peptide libraries [30]. In 1990, McCafferty and 
colleagues [31] demonstrated that it was also possible to fuse genes that encode an 
entire antibody domain, in the form of a scFv to the sequence of one of the bacte-
riophage’s coat proteins. This approach allowed that this methodology could also be 
used for the selection of bacteriophages that recognize antigens.
Later, in 1994, Winter refined the Phage Display technology through a guided 
selection strategy of human antibody fragments from Phage Display repertoires for 
a single-antigen epitope, using rodent MAbs as a model [32]. The first all-human 
antibody produced, using Winter’s Phage Display technique, to be marketed for use 
in humans was adalimumab (Humira), approved by the United States Food and 
Drug Administration (FDA) in 2002 for the treatment of rheumatoid arthritis [33]. 
It is noteworthy that George P. Smith and Gregory P. Winter received the Nobel 
Prize in chemistry in 2018 for the Phage Display of peptides and antibodies (Nobel 
Prize, 2018), a true tool for molecular evolution in vitro emphasizing the impor-
tance of this technique in obtaining biomolecules for various applications.
Phages are single-stranded viruses that infect Gram-negative bacteria and 
are used mainly for the purpose of gene cloning and expression of recombinant 
proteins, in addition to basic molecular biology studies. The particle coating is 
composed of five different proteins, pIII, pVI, pVII, pVIII, and pIX; proteins 
responsible for DNA replication include pII, pV, and pX; and the assembly proteins 
are pI, pIV, and pXI. All of the five proteins contribute to the stability of the phage 
particle; however, pIII is also necessary for the recognition and infection of the host 
cell [33]. Through genetic manipulation, sequences of billions of peptides, protein 
variants, and antibody fragments can be cloned into a vector associated with the 
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phage coat protein gene, the pIII protein being the most commonly used [34]. 
Thus, the Phage Display methodology explores the possibility of direct binding 
of a certain protein (phenotype) with its cognate gene (genotype) by means of a 
phage [35].
3.1 Antibody Phage Display
Beyond the Phage Display and hybridoma technique, other strategies used 
for MAb production include immortalization of human B lymphocyte isolated 
from naturally infected or immunized individuals. One of the approaches for B 
lymphocyte immortalization is using Epstein-Barr virus (EBV). EBV is a human 
tumor virus that was shown to infect efficiently human B lymphocytes and induce 
continuous proliferation in vitro, opening a new perspective for the production 
of human MAbs [36]. Another relevant alternative for MAb production involves 
transgenic animals where mice are genetically manipulated to produce human 
immunoglobulin. In this strategy, genes of human immunoglobulins are inserted 
into mice genome replacing the endogenous sequences, making these animals 
capable to produce fully human antibodies when immunized with an antigen [37].
Among the existing methodologies of antibody production, the hybridoma tech-
nique remains the most widely used. However, the production steps are laborious 
and dependent on the animal immune system. In addition, the heterologous char-
acter of these proteins often makes them immunogenic to humans, provoking the 
response of human anti-mouse antibodies (HAMA), which restrict their therapeutic 
use [34]. Therefore, the Phage Display has emerged as one of the main alternatives 
for the generation of human recombinant MAbs. The major advantages of using the 
Phage Display, in contrast to the hybridoma technique, are clearly the absence of the 
use of animals in the process and the less time to obtain antibodies. The conventional 
method requires immunization which, depending on the type of antigen, can take 
weeks to produce sufficient immune response to produce specific antibodies [38].
There are important advantages and disadvantages between techniques for 
obtaining human MAbs. With the Phage Display technology, it is possible to isolate 
antibodies against all types of antigens, even those with high complexity; differ-
ently, the immortalization technique of human lymphocytes does not allow the 
isolation of antibodies against own antigens or non-immunogenic antigens [39]. 
In addition, only the Phage Display allows the optimization of MAbs, for example, 
by affinity maturation, and in general, the development of antibodies on the Phage 
Display tends to be faster than in other methods [40].
In addition to being robust due to the high stability of the phage, the Phage 
Display also allows control over biochemical parameters throughout the selection 
process. The particular advantage of having control over biochemical parameters 
during the time of selection can also be used to shape the specificity profile of an 
antibody from the start [41]. Table 1 described the MAbs with FDA approval that 
was developed using the Phage Display technique.
Since 1990, different antibody formats have been employed in the construction 
of antibody Phage Display libraries (APDLs). Although antibody libraries are one 
of the most successful tools of Phage Display, the appropriate choice of antibody 
library is an important step for the success of antibody selection. Full-length 
antibodies in the immunoglobulin format are large (150 kDa), complex, and not 
suitable for Phage Display. Therefore, smaller antigen-binding fragments are used. 
For this reason, APDLs are in most cases constructed in either scFv (25 kDa), Fab 
(50 kDa), or single-domain antibody (sdAb) formats which are smaller and more 
effective, although each antibody format has its own advantages and limitations 
[42]. Particularly, sdAbs have received a growing interest as a promising antibody 
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class compared with those conventional. Their more hydrophilic structure, easy 
molecular manipulation, convex surface, and long CDRs enable them to recognize 
cryptic and inaccessible epitopes for typical antibody fragments [43].
There are many kinds of APDLs; they can be classified into two main types: 
natural APDL and synthetic APDL. This classification is based on the source of VH 
and VL genes. Natural APDL comprises immune libraries and naïve libraries, while 
synthetic APDLs comprise semisynthetic libraries and fully synthetic libraries [44]. 
The immune libraries use V-genes that already passed to the clonal selection and 
encode antibodies with high affinity and specificity against the target antigen. The 
immune APDLs have some advantages compared to other libraries, once they have 
the possibility to be explored for understanding the humoral responses in the spe-
cific disease. However, some limitations regarding this library are associated with 
the toxicity of some antigens and some ethical issues, which consequently impair 
the feasibility to active immunization of humans or other animals for obtention of 
antibody repertoires [41, 44].
The naïve APLD involves the generation of libraries that allows the discovery of 
MAbs against all types of antigen. These libraries are produced through the reper-
toires of healthy donors, and antibody genes contained have much more diversity 
than immune libraries. The main advantage of using naïve libraries is the possibility to 
isolate MAbs against non-immunogenic and toxic antigens. However, the major draw-
back is that the selected MAbs often have low affinities compared with antibodies 
from immune libraries [33]. The semisynthetic APLD is based on the display of artifi-
cially made diversity in V-gene segments, usually by in vitro randomization of CDRs 
from a limited number of naïve variable regions, reconstructing the V-gene reper-
toires [41]. One of the characteristics of these libraries is the absence of natural biases 
and redundancies usually found in a naïve library. Unlike semisynthetic APDLs, the 
Antibody Target Format Indication Company Year
Humira 
adalimumab
TNF-α Human Rheumatoid arthritis 
and Crohn’s disease
Abbott 2002
Lucentis 
Ranibizumab
VEGF-A Humanized Macular degeneration Genentech 2006
Simponi 
Golimumab
TNF-α Human Rheumatoid arthritis Johnson & 
Johnson
2009
Benlysta 
Belimumab
BLys Human Systemic lupus 
erythematosus
GSK 2011
Pending 
Raxibacumab
PA Human Anthrax infection 
(Bacillus anthracis)
GSK 2012
Cyramza 
Ramucirumab
VEGFR2 Human Gastric cancer Lilly 2014
Bavencio 
Avelumab
PD-L1 Human Merkel cell carcinoma Serono 2017
Tremfya 
Guselkumab
IL-23 Human Plaque psoriasis Janssen 
Biotech
2017
Gamifant 
Emapalumab
IFNγ Human Hemophagocytic 
lymphohistiocytosis
Swiss 2018
TNF-α, tumor necrosis factor alpha; VEGF-A, vascular endothelial growth factor A; BLys, B lymphocyte stimulator; 
PA, protective antigen; VEGFR2, vascular endothelial growth factor receptor 2; PD-L1, programmed death-ligand 1; 
IL-23, interleukin-23; IFNγ, interferon-γ
Table 1. 
Monoclonal antibodies obtained by Phage Display with FDA approval.
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fully synthetic library is constructed through the incorporation of nucleotide random-
ization based on in silico design and de novo synthesis. This refined synthesis appears 
to increase the functional size of library and consequently the isolation of MAbs with 
a great range of affinity. However, they still need to be optimized regarding their 
binding sites, affinity, valency, and other characteristics [41, 44].
Except in the case of fully synthetic libraries, generally, the construction of an 
antibody library is based on the amplification of the repertoire of the variable chain 
genes of one or more individuals using primers that cover all families of this gene. 
Subsequently, a random combination of the VL and VH chain is generated. In the 
case of the production of Fab libraries, a step is taken to join each variable chain 
fragment with its respective constant region. The PCR products of these amplifica-
tions, representing the antibody repertoire, are ligated into a phagemid vector and 
transformed into E. coli. However, phage vectors generally have only the origin of 
replication of the phage; they do not contain all the genes necessary for replica-
tion and assembly of these phages. Thus, screening libraries using this phagemid 
requires a helper phage to provide replication and assembly proteins. The addition 
of the phage to the bacterial cells transformed with the phagemid will result in the 
production of a mixture of phages that will present predominantly the phagemid 
vector [45].
Once assembled, each phage exposes a fragment of functional antibody fused to 
one of the phage surface proteins [46, 47]. A determining factor for the quality of a 
library and consequently the success of a biopanning by Phage Display is its initial 
diversity, given by the number of different antibodies in the library. The greater the 
initial diversity of clones within the library, the greater the likelihood of containing 
sequences that will bind to a given target with greater affinity [45]. The capacity to 
produce very large libraries (1012 different clones) has turned the Phage Display 
into a fast and reliable high-throughput screening methodology [43].
Most biopanning methods are based on four main steps, preparing a library; 
incubation of that library with a given antigen; removal of nonspecific or low-
affinity phages; and recovery of binding targets, which will be amplified after 
infection in E. coli and used in the next biopanning cycle (Figure 2). The Phage 
Display biopanning process is characterized by an increase in the number of clones 
with affinity for the target molecule through successive selection cycles, with a con-
sequent reduction in the diversity of clones and in the presence of clones with low 
affinity [48]. Thus, the biopanning results in the sequential enrichment of phages 
that have a specific binding to the antigen.
These biopanning steps are usually repeated three to five times, until a high 
specificity/affinity ligand is identified [34, 45, 46]. During biopanning, phage 
binding to the antigen is retained on the plate, and, after a series of washes, these 
phages are eluted and amplified. Subsequently, the phages are again incubated with 
the antigen in the next cycle. Phages with low affinity for antigens may stick to the 
plate, not interacting with the particle, or remain suspended in the solution. After 
the wash step, many of these nonspecific phages are removed. Generally, this step 
involves the application of a greater wash stringency in each subsequent round, 
which can be performed by increasing the number of washes or increasing the 
concentration of the nonionic detergent buffer used.
3.2 Post-selection step
During the biopanning stage, it is possible to monitor the enrichment of 
antibodies by measuring the phage titers that enter the selection and the phage 
titers that are eluted, assessing the enrichment ratio at each selection cycle. The 
enrichment follow-up provides the assurance that the selection was carried out 
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efficiently and is followed by the analysis of the selection progress and the iden-
tification of the antibodies that have greater affinity to the target antigen [49]. 
Over the decades, different ways of analyzing selection have been reported, 
depending on the selection system employed, the antibody library used, and the 
antigen of interest. However, two methods stand out for the quality of the results 
they offer, a monoclonal analysis of a sample of the selected antibodies and a 
polyclonal analysis of the sequences of the entire antibody population.
From the population of selected phages or using cultures of the selected soluble 
antibodies, the specific binding of individual clones to the immobilized antigen is 
assessed in an ELISA assay. In this monoclonal ELISA, the binding of 30–100, or 
more, randomly chosen clones is compared with each other and with the negative 
control. Phages with the highest absorbance values are considered the ones that 
have displayed functionally antibodies of greater affinity. Positive clones for the 
binding analysis are subjected to a Sanger sequencing reaction to determine 
the sequences of the antibodies [50–52]. In this type of Phage Display analysis, 
the  phenotypes (activity) of the antibodies are investigated first and then their 
genotype is determined. The disadvantage of this type of analysis is that it does not 
allow exploring the antibody population in depth and may not include all antibod-
ies of greater affinity. In addition, it does not allow the study of the magnitude of 
selection and enrichment [53].
A high-throughput sequencing provides a tool for rapid analysis of the selection 
and direct identification of the most enriched antibodies, with greater affinity, 
Figure 2. 
Biopanning steps. Representation of a biopanning process characterized by a step of Phage Display library 
incubation with the target antigen, removal of unbound phages, elution of bound phages, and phage 
amplification in E. coli, followed by another cycle. After 3–5 cycles post-selection step is carried out.
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without requiring a step of their expression. In addition to the speed of analysis, it 
is possible to investigate the original diversity of the library; identify all antibodies 
that enriched, the most enriched, and the rare in the population; and determine the 
frequency of increase throughout the selection. This is possible because sequenc-
ing technologies, called next-generation sequencing (NGS), are used, and they 
allow sequencing a large number of sequences, in the order of millions, in the same 
sequencing reaction [54]. The interpretation of NGS results from antibody libraries 
requires the use of a bioinformatics tool specialized in calculating the enrichment of 
variable domains in a selection of Phage Display. Different tools for this purpose are 
described in the literature, such as the recent ATTILA pipeline [55].
Despite providing a profound assessment of all antibodies in all cycles, two 
major problems arise in the analysis of biopanning by sequencing. The first cor-
responds to the noise in the identified final sequences that results from the sequenc-
ing process or the gene amplification reaction. However, more accurate pipelines for 
isolating DNA libraries for sequencing and more powerful bioinformatics analysis 
programs have been produced to overcome the artifacts introduced by PCR and 
sequencing errors. The second is the limitation of the high-performance sequenc-
ing methodology that, although it allows the sequencing of millions of sequences, 
can only properly read up to 400 base pairs. Therefore, this analysis requires that 
the variable domains of the heavy and light chain of antibodies, whose size ranges 
from 300 to 400 base pairs, be amplified and sequenced separately, resulting in the 
loss of the VH and VL pairs of the most enriched antibodies. Recently, studies have 
been carried out to provide a method of sequencing without losing the VH and VL 
pairs of antibodies. In the analysis of the selection process by a high-throughput 
sequencing, the antibody’s genotype is first determined and then their phenotype is 
characterized [53, 56, 57].
4.  Application of Phage Display in the context of DENV and other 
flavivirus infections
The use of MAbs against an infection pathogen is an area of great interest for 
research. In Table 2 it is demonstrated MAbs developed for infection disease who 
have been approved by the FDA. As can be seen, few MAbs are approved for use 
in infectious diseases, although there is still a strong demand for development in 
this field. Some challenges involving MAb production against pathogens are their 
economic viability due to their high cost and if target an episodic disease, there is 
no supporting for continued production. Moreover, there is a concern about the 
selection of neutralization-escape mutants [58]. However, they may be notably 
effective for certain emerging infectious diseases, in which the process of vaccine 
development could be lengthened and difficult. Thus, MAbs should have more 
effectiveness for the first response against these diseases [57].
Small molecules are most antibiotic antivirals. However, Phage Display-derived 
MAbs have an overall success rate of 35% of passage from clinical phase I to 
launch, compared to an average of 12% for a small-molecule drug candidate [59]. 
In this regard, Phage Display-derived MAb is considered an important alternative 
approach to infectious disease treatment compared to classical small-molecule 
discovery. Raxibacumab is an example of a fast-track designation from the FDA, 
providing the expedition of the drug to use against B. anthracis infection. This 
bacterium secretes proteins, the lethal factor and the edema factor, that inhibit 
normal immune system functioning that ultimately cause cell death. The entry 
of these factors is mediated by the protective antigen (PA), also secreted by the 
bacteria. Raxibacumab is directed to B. anthracis PA and thus prevents the cellular 
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uptake of the lethal factor and edema factor. The MAb was developed by the Phage 
Display, using a library licensed by Human Genome Sciences (HGS), which now is 
GlaxoSmithKline (GSK), from Cambridge Antibody Technology. Recombinant PA 
was used in the biopanning process to select candidates, which were then screened 
in assays for PA neutralization [60, 61].
The Phage Display technology provides a rapid methodology for building a high-
affinity antibody library from immune repertoires. These antibodies can be used to 
generate diagnostic bases or be tested for therapeutic capability. For example, from 
the repertoire of B cells of patients who recovered from influenza virus infections 
or who received vaccination, it was possible to isolate, by Phage Display, several 
antibodies with the neutralization property of different influenza virus subtypes. 
Another example of antibody-based immunotherapy developed by Phage Display 
involves the identification of antibodies specific to different types of coronavirus. 
These studies are an example of how Phage Display enables the selection of antibod-
ies by an in vitro process, especially for new or mutated pathogens in an outbreak of 
emergent infectious diseases, as it uses only pathogen-specific antigens [39, 62, 63].
Particularly, MAbs play an important role in antiviral immunity preventing viral 
replication and disease progress. Antibodies can interfere with virus infection by vari-
ous mechanisms. The primary mechanism is by targeting the virus surface proteins; 
antibodies can inhibit virus attachment to cell surface receptors. Another main 
mechanism is targeting non-receptor-binding regions, such as in endosomal mem-
brane fusion step where neutralization can occur by interfering virus conformational 
changes. In general, flavivirus particles tend to display on their surface continuum epi-
topes that induce potently neutralizing antibodies, blocking viral entry into cells [58].
From the understanding of the structure of each flavivirus, it was possible to 
determine the antibody targets most conducive to the diagnosis and protection of 
the disease [64]. It is important to note that flaviviruses are not static particles and 
viral proteins are in a constant dynamic movement, a process known as breathing, 
in order to transiently reveal new epitopes, and this characteristic influences the 
detection and neutralization capabilities of antibodies [10].
So far, no MAbs against flavivirus have reached the clinical stages, except for 
WNV. However, several studies have demonstrated potentially neutralizing MAbs 
that could be therapeutically used against these infections [65, 66]. Different 
antibodies have been generated exploring the characteristics of viral epitopes. The E 
glycoprotein is the main target of neutralizing antibodies, especially the E DIII has 
Antibody Target Format Indication Company Year Method
Pending 
Raxibacumab
PA Human Anthrax 
infection 
(Bacillus 
anthracis)
GSK 2012 Phage 
Display
Zinplava 
Bezlotoxumab
Toxin B Human Clostridium 
difficile 
infection
Merck/
Dohme
2016 Transgenic 
mice
Trogarzo 
Ibalizumab
CD4 Humanized HIV 
infection
TaiMed 2018 Hybridoma
Synagis 
Palivizumab
RSV F Humanized Respiratory 
syncytial 
virus (RSV) 
prophylaxis
MedImmune 1998 Hybridoma
PA, protective antigen; CD4, cluster of differentiation 4; RSV F, respiratory syncytial virus fusion
Table 2. 
Monoclonal antibodies for infectious diseases approved by the FDA.
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been described to be the most efficient to block adsorption of DENV in vitro [58]. 
In the field of DENV diagnosis, MAbs have been especially applied to distinguish 
DENV serotypes [67, 68]. For this purpose E and soluble NS1 proteins are the main 
targets of these MAbs using different assay formats, such as ELISA and rapid test 
based on immunochromatography [69].
The pre-existing cross-reactive antibodies can be boosted in a secondary infec-
tion with antigenically related molecules; consequently antibody to fusion loop tends 
to have dominance upon sequential infections with DENV or other flaviviruses. 
Antibodies to E-dimer epitope (EDE) are divided into two subclasses, EDE1 and EDE2, 
based on the recognition of the conserved glycan Asn-153 of DENV [58]. EDE1 has 
already been shown to potently neutralize ZIKV infection; this class of antibody does 
not require glycosylation for binding [70]. However, EDE2 have a reduced neutraliza-
tion potential against ZIKV, once these antibodies have a strongly binding dependence 
on the glycan, which have different positioning between ZIKV and DENV [66].
The generation of monoclonal antibodies by Phage Display can help improve 
the speed at which new antibodies are produced. The freedom associated with 
recombinant antibodies also allows them to be customized for various applications, 
allowing the development of MAbs with binding, functional, and pharmacological 
characteristics suitable for a therapeutic and diagnostic use [37]. Thus, the use of 
Phage Display to identify antibodies against DENV, as well as for other flavivirus, can 
contribute to the knowledge of the specific antigenic properties of the virus, allow-
ing to generate new perspectives for the development of efficient therapies, vaccines, 
and diagnostic platforms of this virus.
To obtain specific antibodies to the DENV, it is possible to employ different 
libraries of Phage Display and distinct selection approaches depending on the pur-
pose. Using a llama immune library, a diagnostic methodology was developed based 
on antibodies capable of binding to the NS1 of the four DENV serotypes, without 
cross-reacting with NS1 of other flaviviruses. The panning was performed with 
immobilized antigen, so that in each round, the phage population was incubated 
with NS1 from one of the serotypes, resulting in phage specific to all forms of NS1. 
To characterize the diagnostic potential of the antibodies, MAbs were addressed 
[71]. Lebani et al. [72] isolate four serotype-specific human antibodies through a 
negative selection strategy. Each MAb was specific for NS1 from a DENV serotype, 
without cross-linking.
In another approach, Cabezas et al. [73] worked with human naïve library to 
obtain a panel of antibody fragments with different specificity toward DENV 
serotypes. The biopanning was made against inactivated DENV-containing super-
natants harvested from infected Vero cells for 4 days with each serotype. These 
supernatants were directly used for Phage Display biopanning. A panel of nine 
scFvs, where seven were specific for DENV2, DENV3, and DENV4 while the other 
two were cross-reactive, was obtained. Silva [74] employed a subtractive biopan-
ning, in which a human Fab Phage Display library was first incubated against ZIKV 
particles, to eliminate the majority of antibodies that binds to this viral particle, 
and nonbinding phages were then incubated against DENV2 particles, followed by 
elution of ligand phages. Analysis by NGS of the pool of phages retrieved after four 
rounds of this biopanning showed that the VH and VL sequences obtained may not 
have cross-reactivity between DENV2 and ZIKV.
Antibody-based DENV infection therapies developed by Phage Display have also 
been reported. Saokaew et al. [75] show that a human scFv specific for DIII was able 
to neutralize DENV2 infection at in vitro assays. The human MAb 5A, originated 
from a selection of Phage Display, has been shown to be specific to the fusion loop, 
both in its pre-fusion conformation to the endocytic membrane, before infection, 
and in its acid-dependent post-fusion conformation, during the final viral infection 
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process, and proved to be a potent neutralizing antibody of different strains of yel-
low fever virus in vitro and in vivo. Thus, MAb 5A prevents both virus attachment 
and fusion. As the fusion loop is a highly conserved antigen, there is a high pos-
sibility that 5A neutralizes other flaviviruses [76]. In the same way, Wu et al. [77] 
identified a panel of human MAbs that target DIII of the ZIKV envelope protein 
from a large Phage Display naïve antibody library. These germline-like antibodies 
bound ZIKV DIII specifically with high affinities. These MAbs neutralized the cur-
rently circulating ZIKV strains and showed a synergistic effect in neutralizing ZIKV 
in vitro and in a mouse model of ZIKV infection.
As an example of Phage Display using immune libraries to select high-affinity 
MAbs, Mwale et al. [78] analyzed the immune response in chicken through the 
determination of the polyclonal immunoglobulin yolk (IgY) against a truncated 
Zika virus envelope protein. They induced an immune response in white leghorn 
laying hens against the ZIKV envelope protein. A high-level titer of anti-ZIKV 
envelope protein antibodies was detected and after constructed two antibody 
libraries; they found some scFvs that showed specific binding activities toward the 
ZIKV envelope protein.
Moreover, Phage Display has been used to find therapeutic antibody fragments 
against nonstructural proteins. A MAb fragment Fab NS3-specific obtained from 
a naïve human Fab Phage Display library was shown to inhibit the ATPase and 
helicase activities of NS3 protein and reduces DENV replication in vitro. The ability 
to inhibit in vitro DENV replication may be exploited in a therapeutic approach 
[79]. Using a human scFv Phage Display library, Poungpair et al. [80] obtained 
two scFv clones that bound specifically to the NS1 of DENV 2, used as antigen in 
phage biopanning. They observed that cells infected with DENV2 and treated with 
selected scFvs had significant reduction of the infectious viral particles in super-
natant. Besides that, the analysis of mimotope/epitope mapping indicated that the 
NS1 sites bound by antibody fragments can lead to interference of the virus replica-
tion by affecting the virus release.
5. Final considerations
Over the years many discoveries have been made aiming for the control and 
treatment of emerging infectious diseases, some of those include the development 
of efficient drugs that could act specifically in the pathogen to eliminate efficiently. 
In this way, MAbs emerged as the main biological drugs for this purpose. Moreover, 
MAbs play an important role in the development of serological diagnostic test that 
could be used for tracking the spread of disease and determining public health pre-
vention measures and clinical care. There are still great questions around the infec-
tion mechanisms by flavivirus, especially related to the cross-reactivity between 
them and the risk of complications. In this way, the use of effective, fast, and robust 
approaches to facilitate the development of flavivirus MAbs is a determinant factor.
The Phage Display technology presents a great potential to provide optimized 
strategies, allowing the obtention of high-affinity human antibodies for a specific tar-
get. Some of the main advantages that make this technology so promising are the pos-
sibility to obtain human MAbs without in vivo immunization; the enormous diversity 
of variant antibodies displayed within a single library; the ability to tailor MAbs 
with the desired properties by using different strategies such as depletion, guided 
selection, and biochemical control; and the possibility to be applied against practi-
cally any kind of target antigen [33]. However, some concerns about Phage Display 
are the dependence of the initial library quality, the difficulties in the post-selection 
step involving analysis and recombinant antibody production, and the possibility of 
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